JP2024534936A - 銅代謝関連疾患又は障害を治療する方法 - Google Patents

銅代謝関連疾患又は障害を治療する方法 Download PDF

Info

Publication number
JP2024534936A
JP2024534936A JP2024514662A JP2024514662A JP2024534936A JP 2024534936 A JP2024534936 A JP 2024534936A JP 2024514662 A JP2024514662 A JP 2024514662A JP 2024514662 A JP2024514662 A JP 2024514662A JP 2024534936 A JP2024534936 A JP 2024534936A
Authority
JP
Japan
Prior art keywords
weeks
subject
years
tetrathiomolybdate
biscoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534936A5 (https=
Inventor
ユージーン スコット スウェンソン，
ウェイ－ジアン パン，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024534936A publication Critical patent/JP2024534936A/ja
Publication of JP2024534936A5 publication Critical patent/JP2024534936A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90287—Oxidoreductases (1.) oxidising metal ions (1.16)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024514662A 2021-09-07 2022-09-06 銅代謝関連疾患又は障害を治療する方法 Pending JP2024534936A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163241441P 2021-09-07 2021-09-07
US63/241,441 2021-09-07
PCT/US2022/042664 WO2023038909A1 (en) 2021-09-07 2022-09-06 Methods of treating copper metabolism-associated diseases or disorders

Publications (2)

Publication Number Publication Date
JP2024534936A true JP2024534936A (ja) 2024-09-26
JP2024534936A5 JP2024534936A5 (https=) 2025-09-17

Family

ID=85507733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514662A Pending JP2024534936A (ja) 2021-09-07 2022-09-06 銅代謝関連疾患又は障害を治療する方法

Country Status (6)

Country Link
US (1) US20240342127A1 (https=)
EP (1) EP4398896A4 (https=)
JP (1) JP2024534936A (https=)
CN (1) CN117915907A (https=)
CA (1) CA3230084A1 (https=)
WO (1) WO2023038909A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023199A1 (en) * 2021-08-17 2023-02-23 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147887B2 (en) * 2014-12-17 2021-10-19 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson disease
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
EP3880809A4 (en) * 2018-11-16 2023-01-11 Encoded Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF WILSON'S DISEASE
EP4243806A1 (en) * 2020-11-13 2023-09-20 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
WO2023023199A1 (en) * 2021-08-17 2023-02-23 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders

Also Published As

Publication number Publication date
US20240342127A1 (en) 2024-10-17
EP4398896A1 (en) 2024-07-17
WO2023038909A1 (en) 2023-03-16
CA3230084A1 (en) 2023-03-16
CN117915907A (zh) 2024-04-19
EP4398896A4 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
Rogers et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study
KR102803161B1 (ko) 윌슨병을 치료하기 위한 비스-콜린 테트라티오몰리브데이트
US11419832B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
Barcelos et al. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial
JP2024534936A (ja) 銅代謝関連疾患又は障害を治療する方法
Lieske et al. PHYOX3: nedosiran long-term safety and efficacy in patients with primary hyperoxaluria type 1
US20250082674A1 (en) Methods of treating copper metabolism-associated diseases or disorders
JP2021532104A (ja) 多発性硬化症の治療及び予防方法における使用のための置換されたアミノ−ピリミジン化合物
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
JP2024539949A (ja) ボクセロトールを投与する方法
US20250312297A1 (en) Reduction of healthcare resource utilization by patients treated with intranasally-administered metoclopramide
CA3084100C (en) Bis-choline tetrathiomolybdate for treating wilson disease
JP2026503721A (ja) 銅代謝関連疾患又は障害（ウィルソン病）の治療における使用のためのテトラチオモリブデン酸
CN117835989A (zh) 治疗铜代谢相关疾病或障碍的方法
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
CN116685334A (zh) 治疗铜代谢相关疾病或障碍的方法
CN121263186A (zh) 用厄达替尼治疗局部晚期或转移性尿路上皮癌

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250908